Inicio
Explorar
nav.journalClub
Tendencias
Más
synapse
⌘+K
Idioma
Español
Español
New Strategy to Quantify Hepatic CYP3A Activity with Deoxyschizandrin as an In Vivo Probe: A V Approach | Synapse
March 3, 2026
New Strategy to Quantify Hepatic CYP3A Activity with Deoxyschizandrin as an In Vivo Probe: A V Approach
XL
Xiaodong Li
CH
Cong Hu
GW
Guilin Wei
Ver todo
Puntos clave
CYP3A activity quantification was successfully achieved using deoxyschizandrin as a probe, enhancing assessment of drug metabolism in the liver.
The probe effectively demonstrated its utility, with results indicating potential applications in personalized medicine for drug safety and efficacy.
Researchers utilized in vivo methods in their analysis, applying a novel approach that may lead to improved metabolic profiling techniques.
This study highlights new opportunities for drug development, but further validation in diverse populations is needed for broader applicability.
Mark Helpful
Me gusta
Save
Guardar
Relay
Compartir
Mark Helpful
Me gusta
Save
Guardar
Relay
Compartir
Cite This Study
Copy
Li et al. (Sun,) studied this question.
synapsesocial.com/papers/69a76093c6e9836116a2d734
https://doi.org/https://doi.org/10.1016/j.dmd.2026.100248